Cumberland Pharmaceuticals (NASDAQ:CPIX) Stock Crosses Above 200 Day Moving Average - Should You Sell?

Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX - Get Free Report) crossed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $3.63 and traded as high as $5.17. Cumberland Pharmaceuticals shares last traded at $5.08, with a volume of 11,577 shares changing hands.

Wall Street Analysts Forecast Growth

Separately, Wall Street Zen raised shares of Cumberland Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a report on Thursday, May 8th.

Cumberland Pharmaceuticals Stock Performance

The firm has a market capitalization of $76.30 million, a PE ratio of -6.62 and a beta of -0.35. The company has a debt-to-equity ratio of 0.41, a current ratio of 1.13 and a quick ratio of 0.99. The company's fifty day simple moving average is $4.67 and its 200 day simple moving average is $3.73.

Cumberland Pharmaceuticals (NASDAQ:CPIX - Get Free Report) last released its quarterly earnings data on Tuesday, May 6th. The specialty pharmaceutical company reported $0.15 EPS for the quarter. Cumberland Pharmaceuticals had a negative net margin of 29.54% and a negative return on equity of 9.50%.

Institutional Investors Weigh In On Cumberland Pharmaceuticals

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Berkshire Asset Management LLC PA bought a new stake in shares of Cumberland Pharmaceuticals during the first quarter valued at about $692,000. Adage Capital Partners GP L.L.C. bought a new stake in shares of Cumberland Pharmaceuticals during the first quarter valued at about $634,000. Informed Momentum Co LLC bought a new stake in shares of Cumberland Pharmaceuticals during the first quarter valued at about $304,000. Walleye Capital LLC bought a new stake in shares of Cumberland Pharmaceuticals during the first quarter valued at about $298,000. Finally, Two Sigma Investments LP increased its position in shares of Cumberland Pharmaceuticals by 94.3% during the fourth quarter. Two Sigma Investments LP now owns 37,649 shares of the specialty pharmaceutical company's stock valued at $89,000 after buying an additional 18,271 shares during the period. 15.51% of the stock is currently owned by institutional investors.

About Cumberland Pharmaceuticals

Cumberland Pharmaceuticals Inc, a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; Sancuso, an injection for the treatment of chemotherapy treatment; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.